In July, British research service provider Envigo appointed Adrian Hardy as President and CEO. Hardy will also join Envigos Board of Directors.
Cell Medica has acquired Swiss antibody specialist Delenex Therapeutics. The deal nets the British cellular therapeutics developer Delenex proprietory antibody fragment platform Pentrabody.
The US has opened the floodgates to cheaper versions of biologic medicines, and analysts predict that by 2020, biosimilar protein meds could seize a significant share of a projected €390bn market. Thats good news for national health services and insurers, which stand to save billions in payouts. As expensive biologics begin to go off-patent, competitors with knockoffs are planning their onslaughts. But for biosimilars to have a future, both physicians and patients have to be sold on the idea – and many of them remain uninformed and unconvinced. The field is at a crucial juncture.
Vienna-based vaccine specialist Themis Bioscience GmbH has secured broad access to a promising virus vaccine vector tech by extending its license agreement with French Institut Pasteur. Its goal: to develop a Zika vaccine.
The BioBLU 0.3f and BioBLU 1f Single-use Vessels allow microbial process development at the highest level.
US-Dutch medical device company EndoStim, developer of neurostimulation therapy for gastroesophageal reflux disease, has named Rohan Hoare as president and CEO. He succeeds founder Bevil Hogg, who will continue to serve the company as a consultant.
Californian biopharma Medivation has agreed to confidential negotiations with its suitors, in particular the French pharmaceutical company Sanofi, which aggressively has buffeted the cancer therapy specialist for months.
The European Commission started an investigation into Illuminas and Sequenoms 2014 patent agreement, UK-competitor Premaitha Health said. The two US companies had agreed to pool their Noninvasive Prenatal Testing IP.
Antibody veteran David Chiswell, Interim CEO and Chair of Cambridge-based antibody developer Kymab, is taking over at the companys helm for good. Kymabs new old CEO is stepping down from his role as Chairman, however.
Cinfa Biotech is shuffling for position on the lucrative biosimilar market. The Spanish-German company has published positive results in a study for a pegfilgrastim copycat with 172 healthy volunteers in Germany.